A closer look · Treatment benefit

What does a
50% reduction mean?

Keep the same percentage reduction. Change the starting risk. See why the number of people affected can be very different.

Invented numbers for learning. Imagine an unwanted event, such as cancer returning, over five years. These figures do not describe any real cancer, study, treatment or individual. They cannot estimate your risk or guide a treatment choice.

The same difference, described two ways.

10 fewer events per 100 people over five years. The absolute reduction is 10 percentage points; the relative reduction is 50%.

Read the explanation

Absolute change: how many fewer?

In the default fictional example, the event occurs in 20 out of 100 people without the additional treatment and 10 out of 100 with it. That is 10 fewer events per 100 people over five years: an absolute reduction of 10 percentage points.

“Percentage points” describes the difference between the two percentages: 20% minus 10%.

Relative change: compared with what?

Ten is half of twenty. That same difference can therefore be described as a 50% relative reduction. It does not mean that 50 out of every 100 people avoid the event because of treatment.

The starting risk, outcome and period of follow-up are needed to understand what the percentage means.

Two more invented examples

  • 4 events become 2 per 100: a 50% relative reduction and a 2-percentage-point absolute reduction.
  • 40 events become 20 per 100: the same 50% relative reduction, but a 20-percentage-point absolute reduction.

Real estimates also have uncertainty. This simple display does not show confidence intervals, competing risks, treatment side effects or the burden of treatment. Those belong in a clinical discussion.

Pause and consider

Two treatments are each described as reducing an event by 50%. Does that tell you they prevent the same number of events per 100 people?

Useful questions for a consultation

  • What outcome are we discussing, and over what period?
  • What are the expected numbers with and without this treatment?
  • How uncertain are those estimates, and how do side effects compare?

Sources & clinical review

Clinically reviewed and approved by Dr AlHilali on 4 November 2026.

Explore the other interactive lessons